Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AEZS Aeterna Zentaris	$3.00 +2.4%	$3.53	$3.96 ▼ $12.00	$5.38M	1.55	7,305 shs	8,904 shs
ALLR Allarity Therapeutics	$1.59 +11.2%	$1.00	$0.61 ▼ $5.94	$20.91M	0.08	19.63 million shs	15.44 million shs
AYTU Aytu BioPharma	$2.33 +2.2%	$2.31	$0.95 ▼ $2.85	$20.47M	0.13	109,158 shs	36,722 shs
IXHL Incannex Healthcare	$0.67 -5.6%	$0.47	$0.08 ▼ $3.12	$20.89M	7.67	177.47 million shs	122.53 million shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AEZS Aeterna Zentaris	-10.90%	+1.38%	-24.87%	-12.28%	-50.00%
ALLR Allarity Therapeutics	+51.92%	+57.99%	+40.20%	+54.11%	-71.39%
AYTU Aytu BioPharma	-0.87%	+3.64%	-13.31%	+19.37%	-3.80%
IXHL Incannex Healthcare	-4.15%	+85.76%	-32.40%	+208.47%	-63.03%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AEZS Aeterna Zentaris	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ALLR Allarity Therapeutics	2.9807 of 5 stars	3.5	5.0	0.0	0.0	3.1	0.0	0.6
AYTU Aytu BioPharma	3.7468 of 5 stars	3.5	2.0	0.0	3.4	3.3	0.0	0.6
IXHL Incannex Healthcare	0.2291 of 5 stars	0.0	2.0	0.0	0.0	2.4	0.8	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AEZS Aeterna Zentaris	0.00	N/A	N/A	N/A
ALLR Allarity Therapeutics	3.00	Buy	$9.00	466.04% Upside
AYTU Aytu BioPharma	3.00	Buy	$10.00	329.18% Upside
IXHL Incannex Healthcare	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest AEZS, ALLR, IXHL, and AYTU Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/28/2025	ALLR Allarity Therapeutics	Ascendiant Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$9.00
7/1/2025	AYTU Aytu BioPharma	Lake Street Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$8.00
6/30/2025	AYTU Aytu BioPharma	Ascendiant Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$12.00

(Data available from 8/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AEZS Aeterna Zentaris	$2.37M	2.27	N/A	N/A	$14.99 per share	0.20
ALLR Allarity Therapeutics	N/A	N/A	N/A	N/A	$0.83 per share	N/A
AYTU Aytu BioPharma	$81M	0.26	N/A	N/A	$4.64 per share	0.50
IXHL Incannex Healthcare	$10K	1,972.69	N/A	N/A	$0.18 per share	3.72

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AEZS Aeterna Zentaris	-$16.55M	-$14.86	N/A	∞	N/A	-760.32%	-83.45%	-45.76%	N/A
ALLR Allarity Therapeutics	-$24.51M	N/A	0.00	N/A	N/A	N/A	-173.31%	-102.57%	11/13/2025 (Estimated)
AYTU Aytu BioPharma	-$15.84M	-$0.72	N/A	∞	N/A	2.37%	3.51%	0.91%	9/25/2025 (Estimated)
IXHL Incannex Healthcare	-$18.46M	-$1.21	N/A	∞	N/A	N/A	-342.92%	-148.64%	9/29/2025 (Estimated)

Latest AEZS, ALLR, IXHL, and AYTU Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/15/2025	Q2 2025	ALLR Allarity Therapeutics	-$0.21	-$0.15	+$0.06	-$0.15	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AEZS Aeterna Zentaris	N/A	N/A	N/A	N/A	N/A
ALLR Allarity Therapeutics	N/A	N/A	N/A	N/A	N/A
AYTU Aytu BioPharma	N/A	N/A	N/A	N/A	N/A
IXHL Incannex Healthcare	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AEZS Aeterna Zentaris	N/A	5.94	5.93
ALLR Allarity Therapeutics	N/A	2.31	2.31
AYTU Aytu BioPharma	0.27	1.03	0.87
IXHL Incannex Healthcare	N/A	2.12	2.12

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AEZS Aeterna Zentaris	0.73%
ALLR Allarity Therapeutics	11.53%
AYTU Aytu BioPharma	33.49%
IXHL Incannex Healthcare	0.43%

Insider Ownership

Company	Insider Ownership
AEZS Aeterna Zentaris	0.10%
ALLR Allarity Therapeutics	0.08%
AYTU Aytu BioPharma	3.60%
IXHL Incannex Healthcare	15.49%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AEZS Aeterna Zentaris	20	1.79 million	1.79 million	No Data
ALLR Allarity Therapeutics	10	14.62 million	14.61 million	Not Optionable
AYTU Aytu BioPharma	160	8.98 million	8.65 million	Not Optionable
IXHL Incannex Healthcare	3	29.43 million	24.88 million	Not Optionable

AEZS, ALLR, IXHL, and AYTU Headlines

Recent News About These Companies

Incannex Reports Positive Results from Phase 2 Clinical Trial of PSX-001 (Psi-GAD) for Generalised Anxiety Disorder

August 26 at 8:00 AM | globenewswire.com

Top Cannabis Stocks To Keep An Eye On - August 23rd

August 26 at 2:13 AM | americanbankingnews.com

Promising Cannabis Stocks To Follow Now - August 24th

August 26 at 2:27 AM | americanbankingnews.com

Best Cannabis Stocks To Consider - August 22nd

August 25 at 5:01 AM | americanbankingnews.com

Top Cannabis Stocks To Follow Now - August 21st

August 24 at 4:13 AM | americanbankingnews.com

This Pharma Stock Soared 23% Today But Is Still Down Over 70% In 2025 – Find Out More

August 22, 2025 | msn.com

Incannex Healthcare Inc. Launches $20 Million Share Repurchase Program to Enhance Shareholder Value

August 22, 2025 | quiverquant.comQ

Incannex Healthcare Authorizes $20 Million Share Repurchase Program

August 22, 2025 | globenewswire.com

Stonegate Updates Coverage on Incannex Healthcare Inc. (IXHL) 3Q 2025 - Update

August 19, 2025 | newsfilecorp.comN

Incannex Healthcare Inc. (IXHL) Receives Positive Patient-Reported Outcomes For IHL-42X in Obstructive Sleep Apnoea

August 17, 2025 | msn.com

Incannex Healthcare: Incannex Receives Positive Patient-Reported Outcomes and Compelling Phase 2 Efficacy Data for IHL-42X in Obstructive Sleep Apnoea

August 9, 2025 | finanznachrichten.de

Incannex Shares Surge Following Promising Sleep Apnea Trial Data

August 8, 2025 | msn.com

Incannex Receives Positive Patient-Reported Outcomes and Compelling Phase 2 Efficacy Data for IHL-42X in Obstructive Sleep Apnoea

August 8, 2025 | globenewswire.com

Incannex Confirms Strong Cash Position; No Plans or Requirement to Fully Utilise ATM in Near Term

July 31, 2025 | globenewswire.com

Incannex reports results from RePOSA Phase 2 trial of IHL-42X

July 30, 2025 | msn.com

Incannex Reports Positive Topline Results from RePOSA Phase 2 Trial of IHL-42X

July 30, 2025 | globenewswire.com

Incannex Healthcare Expands Clinical Advisory Board to Support Obstructive Sleep Apnea Program with Appointment of Dr. Charlene E. Gamaldo

July 25, 2025 | globenewswire.com

Incannex Expands ATM Offering by $100 Million

July 24, 2025 | tipranks.com

IXHL - Incannex Healthcare Inc News - Morningstar

July 19, 2025 | morningstar.comM

Incannex Healthcare Ltd ADR News (IXHL) - Investing.com

July 3, 2025 | investing.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

AEZS, ALLR, IXHL, and AYTU Company Descriptions

Aeterna Zentaris NASDAQ:AEZS

$3.00 +0.07 (+2.39%)

As of 08/26/2025

Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests in Canada, Switzerland, Ireland, Denmark, Germany, the United States, and internationally. Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of patients with adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as endocrinology and oncology indications; AEZS-150, a delayed clearance parathyroid hormone fusion polypeptide that is in preclinical trial for the treatment of chronic hypoparathyroidism; and AEZS-130 that is in preclinical trial for the treatment of amyotrophic lateral sclerosis. The company also has a license and research agreement with University of Wuerzburg to develop, manufacture, and commercialize AIM biologicals for the treatment of neuromyelitis optica spectrum disorder; and for pre-clinical development towards the potential treatment of Parkinson's disease. In addition, it has a license agreement with Consilient Health Ltd. and NK MEDITECH Ltd. for the development and commercialization of macimorelin; a distribution and commercialization agreement with Er-Kim Pharmaceuticals Bulgaria Eood for the commercialization of macimorelin for the diagnosis of growth hormone deficiency in children and adults; as well as The University of Sheffield, the United Kingdom for the development, manufacture, and commercialization of parathyroid hormone fusion polypeptides for the treatment of chronic hypoparathyroidism. Aeterna Zentaris Inc. was incorporated in 1990 and is headquartered in Toronto, Canada.

Allarity Therapeutics NASDAQ:ALLR

$1.59 +0.16 (+11.19%)

Closing price 04:00 PM Eastern

Extended Trading

$1.57 -0.02 (-1.26%)

As of 08:00 PM Eastern

Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA (ixabepilone), a selective microtubule inhibitor in phase 2 for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme. Allarity Therapeutics, Inc. has a collaboration with Detsamma Investments Pty. Ltd. to develop Deflexifol for the treatment of solid tumors. The company was incorporated in 2004 and is headquartered in Boston, Massachusetts.

Aytu BioPharma NASDAQ:AYTU

$2.33 +0.05 (+2.19%)

Closing price 04:00 PM Eastern

Extended Trading

$2.41 +0.08 (+3.43%)

As of 07:31 PM Eastern

Aytu Biopharma, Inc. is a specialty pharmaceutical company, which engages in identifying, acquiring, and commercializing novel products. It operates through the Rx and Consumer Health segments. The RX segment consists of various prescription pharmaceutical products sold through third parties. The Consumer Health segment includes various consumer health products sold directly to consumers. Its products include Adzenys ER, Adzenys XR-ODT, Cotempla XR-ODT, Karbinal ER, Poly-Vi-Flor, Tri-Vi-Flor, Generic Tussionex, Tuzistra XR, and ZolpiMist. The company was founded on August 9, 2002 and is headquartered in Englewood, CO.

Incannex Healthcare NASDAQ:IXHL

$0.67 -0.04 (-5.56%)

Closing price 04:00 PM Eastern

Extended Trading

$0.67 +0.00 (+0.25%)

As of 07:59 PM Eastern

Incannex Healthcare Inc., a clinical stage pharmaceutical development company, engages in the research, development, and sale of medicinal cannabinoid and psychedelic pharmaceutical products and therapies. It develops products for the treatment of obstructive sleep apnoea (OSA), traumatic brain injury (TBI) and concussion, lung inflammation (ARDS, COPD, asthma, bronchitis), rheumatoid arthritis, inflammatory bowel disease, anxiety disorders, addiction disorders, pain, and other indications. The company offers APIRx-1801, an ultrapure tetrahydrocannabinol; APIRx-1802, an ultrapure CBD; and APIRx-1803, an ultrapure cannabigerol. It also develops IHL-42X, which has completed Phase IIb clinical trial for obstructive sleep apnea; Psi-GAD that is in Phase IIa clinical trial for generalized anxiety disorder; MedChew Dronabinol, which has completed Phase Ia clinical trial for nausea and vomiting in chemotherapy; CanChew Plus that has completed Phase IIa clinical trial for irritable bowel syndrome; APIRx-1601, which has completed Phase IIa clinical trial for vitiligo; APIRx-1602 skin that has completed Phase IIa clinical trial for psoriasis; and APIRx-1603, which has completed Phase IIa clinical trial for atopic dermatitis. In addition, its product portfolio includes IHL-675A for inflammatory lung disease, IHL-675A for rheumatoid arthritis, IHL-675A for inflammatory bowel disease, and IHL-216A for traumatic brain injury and concussion, which have completed pre-clinical trials; and MedChew 1401 for pain and spasticity in multiple sclerosis, MedChew GB for post-herpatic neuralgia, MedChew-1502 for Parkinson's disease, MedChew-1503 for dementia, MedChew RL for restless legs syndrome, APIRx 1505 Flotex for chrohn's disease, CanChew RX and SuppoCan (Suppository) for inflammatory bowel disease, CheWell for addiction of cannabis, CanQuit for tobacco smoking cessation, CanQuit O for opioid addiction, APIRx-1701 for glaucoma, suppoCan gastro for IBD, and APIRx-1702 for dry eye syndrome that are in pre-clinical trials. Incannex Healthcare Inc. was incorporated in 2001 and is based in Sydney, Australia.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time